This medication conflict checker helps acromegaly patients find out if their current medications could affect clinical trial eligibility. Select one or more medications below to instantly screen active trials for potential conflicts.
Acromegaly treatment often involves multiple medications working together: a somatostatin analog to lower growth hormone, possibly pegvisomant or a dopamine agonist as add-on therapy, plus medications for the comorbidities that come with the disease like diabetes, hypertension, and joint pain. Each clinical trial publishes eligibility criteria that may exclude specific drugs or drug classes, and these vary significantly from trial to trial.
Somatostatin Analogs (SRLs)
Sandostatin LAR, Somatuline Depot, Signifor LAR, Mycapssa, Palsonify — trials testing new mechanisms of action frequently exclude patients on current SRL therapy or require a washout period of 3 to 6 months. Octreotide, lanreotide, pasireotide, oral octreotide, and paltusotine are the most commonly excluded drugs in acromegaly trials.
GH Receptor Antagonist
Somavert (pegvisomant) — because pegvisomant normalizes IGF-1 through a different mechanism than SRLs, many trials exclude it to avoid confounding results. Washout periods of 8 weeks to 12 months are common. Some combination studies actually require patients to be on a stable SRL dose while excluding pegvisomant.
Dopamine Agonists
Dostinex (cabergoline), Parlodel (bromocriptine) — used as adjunctive therapy in patients with mild IGF-1 elevation or co-secreting prolactin. Trials may exclude dopamine agonists or require a 4-week to 3-month washout. Shorter washout than SRLs due to faster clearance.
Comorbidity Medications
Diabetes, blood pressure, pain, and mood medications — acromegaly commonly causes diabetes (30-50% of patients), hypertension (37-40%), joint pain, and depression. These comorbidity medications are rarely the reason a trial excludes you. When they appear in eligibility criteria, the language usually says uncontrolled diabetes or unstable blood pressure rather than banning the medications outright.
If you take pasireotide (Signifor): a note about diabetes medications
Pasireotide causes hyperglycemia in 30-70% of patients, so many people on Signifor also take metformin, insulin, or other diabetes medications specifically because of their acromegaly treatment. If the checker flags your diabetes medication at low confidence, that's because the trial mentions diabetes or glucose in broad terms. It doesn't necessarily mean you're excluded. The study team will evaluate your specific situation, including whether your diabetes is medication-induced and well-controlled.
A conflict doesn't always mean you can't join
Many conflicts come with a washout period, meaning you may be able to participate if you stop the medication for a certain amount of time before the trial starts. For example, a trial might require stopping octreotide for 6 months or pegvisomant for 8 weeks. Whether a washout is safe and feasible depends on your disease activity and should always be discussed with your endocrinologist. The checker shows washout periods when the trial specifies them.
Had pituitary surgery? Your hormone replacements are usually allowed
Post-surgical patients often take hydrocortisone, levothyroxine, desmopressin, or sex hormones to replace what the pituitary gland no longer produces. Even when a trial excludes glucocorticoids or steroids, there is typically an exception for physiologic replacement doses. If the checker flags one of your replacement hormones, check the excerpt text carefully. You'll often see language like except physiologic replacement or stable hormone substitution permitted.
Don't see your medication listed?
The checker covers 34 medications across 11 categories that are most relevant to acromegaly patients, including acromegaly-specific treatments, diabetes medications, blood pressure medications, pain medications, psychiatric medications, thyroid replacement, and post-surgical hormone replacement. If your medication isn't in the list, that means we haven't found it commonly mentioned in acromegaly trial exclusion criteria. You should still tell the study team about all medications you take when you contact them.
How the medication conflict checker works: This free tool helps acromegaly patients learn if their current medications could affect clinical trial eligibility. It scans the published eligibility criteria of every active acromegaly clinical trial and flags which ones may exclude your specific treatment. Matches are categorized by confidence level: high confidence means the trial names your exact drug, medium confidence means it references your drug class, and low confidence means it uses broad category language that may or may not apply to you. Select one or more of your medications above to instantly see which trials you may still qualify for and which ones could be a problem. Always confirm eligibility directly with the study team, as final decisions involve your complete medical history, hormone levels, imaging, and your endocrinologist's assessment.
Across 1,853 open rare disease treatment trials, a third exclude people over a medication they commonly take. See which medications and diseases, in our September 2026 analysis.
